Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Panacea Biotec Ltd

    Panacea Biotec is the largest Vaccine manufacturing Company in India and is well acknowledged by the UN Health Agencies in partnering the Polio eradication initiative with suppl

  • No Image
    Panchsheel Organics Ltd

    Panchsheel an ISO 9001 : 2008 certified GMP approved public listed company (with listing on BSE) are manufacturers and exporters of Active Pharma Ingredients(APIs), Intermediate

  • No Image
    Par Drugs Chemicals Pvt Ltd

    Par Drugs & Chemicals Pvt Ltd is a Bhavnagar (Gujarat) based company promoted by the Savani family and is engaged in manufacturing basic chemicals including Aluminium and Magnes

  • No Image
    Parabolic Drugs Ltd

    Parabolic Drugs Limited(PDL) , founded in 1996, is engaged in contract manufacture of APIs and API intermediates. In the year 2011, the company has stepped up in the value chain